Abstract

The initial steps of B-cell acute lymphoblastic leukemia (B-ALL) development usually pass unnoticed in children. Several preclinical studies have shown that exposure to immune stressors triggers the transformation of preleukemic B cells to full-blown B-ALL, but how this takes place is still a longstanding and unsolved challenge. Here we show that dysregulation of innate immunity plays a driving role in the clonal evolution of pre-malignant Pax5+/− B-cell precursors toward leukemia. Transcriptional profiling reveals that Myd88 is downregulated in immune-stressed pre-malignant B-cell precursors and in leukemic cells. Genetic reduction of Myd88 expression leads to a significant increase in leukemia incidence in Pax5+/−Myd88+/− mice through an inflammation-dependent mechanism. Early induction of Myd88-independent Toll-like receptor 3 signaling results in a significant delay of leukemia development in Pax5+/− mice. Altogether, these findings identify a role for innate immunity dysregulation in leukemia, with important implications for understanding and therapeutic targeting of the preleukemic state in children.

Immunological stressors are linked to the transformation of preleukemic B cells to B-cell acute lymphoblastic leukemia. Here the authors show a dysregulation of innate immune signaling in preleukemic precursor B cells and link to the development of B-cell acute lymphoblastic leukemia in a murine model.

Details

Title
Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice
Author
Isidro-Hernández, Marta 1   VIAFID ORCID Logo  ; Casado-García, Ana 1 ; Oak, Ninad 2   VIAFID ORCID Logo  ; Alemán-Arteaga, Silvia 1   VIAFID ORCID Logo  ; Ruiz-Corzo, Belén 1 ; Martínez-Cano, Jorge 3   VIAFID ORCID Logo  ; Mayado, Andrea 4 ; Sánchez, Elena G. 5 ; Blanco, Oscar 6 ; Gaspar, Ma Luisa 7   VIAFID ORCID Logo  ; Orfao, Alberto 4   VIAFID ORCID Logo  ; Alonso-López, Diego 8   VIAFID ORCID Logo  ; De Las Rivas, Javier 9   VIAFID ORCID Logo  ; Riesco, Susana 10   VIAFID ORCID Logo  ; Prieto-Matos, Pablo 11   VIAFID ORCID Logo  ; González-Murillo, África 5   VIAFID ORCID Logo  ; Criado, Francisco Javier García 12 ; Cenador, María Begoña García 12 ; Ramírez-Orellana, Manuel 5   VIAFID ORCID Logo  ; de Andrés, Belén 7   VIAFID ORCID Logo  ; Vicente-Dueñas, Carolina 11   VIAFID ORCID Logo  ; Cobaleda, César 3   VIAFID ORCID Logo  ; Nichols, Kim E. 2   VIAFID ORCID Logo  ; Sánchez-García, Isidro 1   VIAFID ORCID Logo 

 CSIC-USAL, Campus M. de Unamuno s/n, Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain (GRID:grid.428472.f) (ISNI:0000 0004 1794 2467); Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4) 
 St. Jude Children’s Research Hospital, Department of Oncology, Memphis, USA (GRID:grid.240871.8) (ISNI:0000 0001 0224 711X) 
 Centro de Biología Molecular Severo Ochoa (Consejo Superior de Investigaciones Científicas -Universidad Autónoma de Madrid), Immune system development and function Unit, Madrid, Spain (GRID:grid.465524.4) 
 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); CSIC/Universidad de Salamanca, Servicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817) 
 Universidad Autónoma de Madrid, Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126) 
 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Universidad de Salamanca, Departamento de Anatomía Patológica, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817) 
 Carlos III Health Institute, Immunobiology Department, Majadahonda (Madrid), Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 Cancer Research Center (CSIC-USAL), Bioinformatics Unit, Salamanca, Spain (GRID:grid.11762.33) 
 Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Bioinformatics and Functional Genomics Research Group, Cancer Research Center (CSIC-USAL), Salamanca, Spain (GRID:grid.452531.4) 
10  Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Department of Pediatrics, Salamanca, Spain (GRID:grid.411258.b) 
11  Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Department of Pediatrics, Salamanca, Spain (GRID:grid.411258.b) 
12  Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain (GRID:grid.452531.4); Universidad de Salamanca, Departamento de Cirugía, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817) 
Pages
5159
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2856659809
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.